2 September 2010

Provexis

SPECULATIVE BUY

08/02/2010

AIM-listed Provexis hopes to soon conclude negotiations with a host of ‘global players’ over deals for its Fruitflow food supplement, which boosts blood circulation.

The Windsor-based company, floated by former GlaxoSmithKline strategist Stephen Moon as Nutrinnovator in 2004, before acquiring Provexis in 2005, has developed Fruitflow from a tomato extract that was first discovered by scientists at Aberdeen University, who were studying the health-giving properties of the Mediterranean diet.

Last year, Fruitflow was one of the first products to be approved under new European Union rules governing healthcare claims on foods. This EU approval allows Fruitflow to be marketed with the words ‘contributes to healthy bloodflow’, which will make it attractive to those at risk from strokes. Moon claims Fruitflow ‘works on virtually everyone’, unlike some current blood-thinning treatments such as asprin, and does not create unwanted side effects, as those other treatments do.  

Fruitflow has been proved, through rigorous human clinical trials, to take effect within three hours of consumption and last for eighteen hours, and Provexis has developed suitable syrups or powders to enable the supplement to be taken daily via ‘functional foods’ or dietary supplements. ‘Significant interest has been received from food and drinks companies as well as ingredients makers,’ says Moon, ‘and we’re in dialogue to see how we can craft a deal.’

Provexis, which added £7m, thanks to a December placing and open offer, to the £2.3m cash it had in the bank in September, is developing other products derived from foods, including an extract from plantain bananas that helps alleviate Crohn's disease, and treatments for peptic ulcers and the C Difficile superbug. Moon says ‘now we’ve got to use the funds and look for new applications and technologies’, either already revenue-generating or at an early-stage.

Floated at 53p as Nutrinnovator, the shares reached a four-year high of 14.88p last year and offer speculators the potential for further gains.

Tags: AIM , Deals & contracts , Fundraisings

Sector: Food Producers

Companies: Provexis

Market cap: £84.19m

PE Forecast: n/a

Share price: 7.6p

Subscribe today


More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.

Subscribe today and save 50%

VCT Report 2010

VCT Report 2010 uncovers the money available

for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted

company.

Order VCT Report 2010 today using this online form

Cash Shells Directory 2010

A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

Take control of your investments

A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.

The Financial Times Guide to Personal Tax

is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.

The AIM Guide Spring 2010

The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).

A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!

Share recommendations and small-cap stock picks

Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.

Popular Recommendations

Latest Recommendations

Delcam 01/09/2010

Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.

Antisoma 01/09/2010

Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.

The Capital Pub Company 31/08/2010

London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.

More Recommendations

Sectors

Vitesse Media Events